Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anemia in multiple myeloma.

Heinz Ludwig1, Gudrun Pohl, Anders Osterborg

  • 1Department of Medicine I, Wilhelminenspital, Vienna, Austria. heinz.ludwig@wienkav.at

Clinical Advances in Hematology & Oncology : H&O
|September 16, 2005
PubMed
Summary

Anemia is common in multiple myeloma (MM). Recombinant human erythropoietin (rHuEPO) offers a long-term solution for anemia in MM patients, improving hemoglobin levels and quality of life without transfusion risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.

EBioMedicine·2026
Same author

Temporal trends in progression risk in smoldering myeloma: a systematic review.

EClinicalMedicine·2026
Same author

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Annals of hematology·2026
Same author

T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.

British journal of haematology·2025

Area of Science:

  • Hematology
  • Oncology

Background:

  • Anemia affects over two-thirds of multiple myeloma (MM) patients.
  • Common causes include anemia of chronic disease (ACD), erythropoietin (EPO) deficiency, and chemotherapy side effects.
  • Anemia often persists in non-responders and relapsing MM patients.

Purpose of the Study:

  • To evaluate recombinant human erythropoietin (rHuEPO) as a treatment for anemia in multiple myeloma (MM).
  • To compare the efficacy and safety of rHuEPO versus red blood cell (RBC) transfusions.

Main Methods:

  • Review of studies investigating rHuEPO treatment for anemia in MM patients.
  • Analysis of reported improvements in erythropoiesis, transfusion requirements, and quality of life.

Main Results:

  • rHuEPO treatment leads to sustained increases in hemoglobin levels.
  • Studies show a significant reduction in the need for RBC transfusions.
  • rHuEPO improves erythropoiesis and patient quality of life without transfusion-related risks.

Conclusions:

  • rHuEPO is an effective and safe long-term treatment for anemia associated with multiple myeloma.
  • International expert panels recommend rHuEPO for anemic MM patients after excluding other causes.
  • rHuEPO offers a viable alternative to RBC transfusions, mitigating associated risks.

Related Experiment Videos